Becton Dickinson & Co (BDX)
224.12
+0.04
(+0.02%)
USD |
NYSE |
Dec 19, 12:40
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 64.80B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -4.16% |
| Valuation | |
| PE Ratio | 37.73 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 3.231 |
| Price to Book Value | 2.503 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 1.04 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.7768 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 29.62% |
Profile
| Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (27% of 2024 revenue) and BD Interventional (24%) account for the remainder. International revenue accounts for 43% of the company's business. |
| URL | https://www.bd.com |
| Investor Relations URL | https://investors.bd.com/ |
| HQ State/Province | New Jersey |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | Feb. 06, 2025 |
| Last Earnings Release | Nov. 07, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Dec. 09, 2024 |
Ratings
Profile
| Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (27% of 2024 revenue) and BD Interventional (24%) account for the remainder. International revenue accounts for 43% of the company's business. |
| URL | https://www.bd.com |
| Investor Relations URL | https://investors.bd.com/ |
| HQ State/Province | New Jersey |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | Feb. 06, 2025 |
| Last Earnings Release | Nov. 07, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Dec. 09, 2024 |